FIND AN INFUSION SERVICE PROVIDER IN YOUR AREA.
You are about to leave the VYEPTI website for healthcare professionals
VYEPTI Dosing and Administration Video Coming Soon
By leaving this page, all selections will be lost. Do you want to continue?
Living with fewer migraine attacks means...freedom."
*The vicious cycle is defined as more frequent or severe migraine days with the continued, increasing need for acute medications over time.1,2
Meet Chanci
Despite being on a preventive treatment, Chanci was trapped in a vicious cycle as the frequency and severity of her migraine attacks increased.
Migraine had taken over Chanci’s life
- Even with the increased use of acute medication, Chanci was unable to get relief
- Chanci’s migraine attacks made her feel like she couldn’t be fully present—in her own life, or in the lives of her friends and family
- Burdened by 10 to 15 migraine days per month, as well as daily headaches, she spent much of her time in a dark, quiet room, avoiding noise and light
Making a change with VYEPTI
After years of Chanci living with migraine, her neurologist recognized a change was needed and prescribed VYEPTI.
Chanci was compensated for her time. Patient results may vary.
My migraine attacks made me feel helpless. I needed to do something different. My neurologist and I decided to try VYEPTI. It's one 30-minute IV infusion, just 4 times a year.
Watch Chanci’s video to learn more about her life with migraine
AHS Symposium Cut V 12LR
Consider VYEPTI for your patients like Chanci
With one 30-minute IV every 3 months, VYEPTI has the potential to help some patients overcome challenges associated with migraine.3
Learn more about VYEPTI in chronic migraine
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Full Prescribing Information and Patient Information.
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Full Prescribing Information and Patient Information.
References:
- Diener HC, Antonaci F, Braschinsky M, et al. European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol. 2020;27(7):1102-1116.
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd ed. Cephalalgia. 2018;38(1):1-211.
- VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
© 2023 Lundbeck. All rights reserved. VYEPTI and VYEPTI GO are registered trademarks, and VYEPTI CONNECT and Migraine Victors Program are trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100032v15
This website is intended for US healthcare professionals only.
